Cargando…

Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum

BACKGROUND: Compounded cantharidin has been used for decades to treat molluscum contagiosum but lacks rigorous clinical evidence to support its safety and efficacy. VP-102 is a shelf-stable drug–device combination product that contains topical cantharidin (0.7% weight/volume [w/v]) and is being eval...

Descripción completa

Detalles Bibliográficos
Autores principales: Eichenfield, Lawrence F., Siegfried, Elaine, Kwong, Pearl, McBride, Mark, Rieger, Jayson, Glover, David, Willson, Cynthia, Davidson, Matthew, Burnett, Patrick, Olivadoti, Melissa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973914/
https://www.ncbi.nlm.nih.gov/pubmed/33599960
http://dx.doi.org/10.1007/s40257-020-00570-8
_version_ 1783666906195034112
author Eichenfield, Lawrence F.
Siegfried, Elaine
Kwong, Pearl
McBride, Mark
Rieger, Jayson
Glover, David
Willson, Cynthia
Davidson, Matthew
Burnett, Patrick
Olivadoti, Melissa
author_facet Eichenfield, Lawrence F.
Siegfried, Elaine
Kwong, Pearl
McBride, Mark
Rieger, Jayson
Glover, David
Willson, Cynthia
Davidson, Matthew
Burnett, Patrick
Olivadoti, Melissa
author_sort Eichenfield, Lawrence F.
collection PubMed
description BACKGROUND: Compounded cantharidin has been used for decades to treat molluscum contagiosum but lacks rigorous clinical evidence to support its safety and efficacy. VP-102 is a shelf-stable drug–device combination product that contains topical cantharidin (0.7% weight/volume [w/v]) and is being evaluated for the treatment of molluscum. OBJECTIVES: Our objective was to present pooled safety and efficacy analyses of VP-102 in the treatment of molluscum compared with vehicle. METHODS: Participants aged ≥ 2 years were randomized 3:2 to topical administration of VP-102 or vehicle in two randomized, double-blind, vehicle-controlled phase III trials. Study drug was applied to all baseline and new lesions once every 21 days until clear or for a maximum of four applications. Assessors blinded to treatment counted all lesions at each study visit. All adverse events (AEs) were documented. Data were pooled for analyses. RESULTS: In total, 310 participants received VP-102 and 218 received vehicle. Mean age was 7.5 years (range 2–60) for VP-102 and 6.8 (2–54) for vehicle. Complete clearance of all molluscum lesions at day 84 occurred in 50% of VP-102 participants and 15.6% of vehicle recipients (p < 0.0001). Mean molluscum lesion counts decreased 76% for VP-102 and 0.3% for vehicle at day 84 (p < 0.0001). The most common AEs in the VP-102 group were application site blistering, pruritus, pain, and erythema, which were generally mild or moderate in severity. CONCLUSIONS: Pooled analyses showed a significantly higher percentage of participants with complete molluscum lesion clearance and larger reductions in lesion counts with VP-102 than with vehicle. AEs were anticipated because of the pharmacodynamic properties of cantharidin. TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT03377790 (first posted 19 December 2017) and NCT03377803 (first posted 19 December 2017). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40257-020-00570-8.
format Online
Article
Text
id pubmed-7973914
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-79739142021-04-05 Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum Eichenfield, Lawrence F. Siegfried, Elaine Kwong, Pearl McBride, Mark Rieger, Jayson Glover, David Willson, Cynthia Davidson, Matthew Burnett, Patrick Olivadoti, Melissa Am J Clin Dermatol Original Research Article BACKGROUND: Compounded cantharidin has been used for decades to treat molluscum contagiosum but lacks rigorous clinical evidence to support its safety and efficacy. VP-102 is a shelf-stable drug–device combination product that contains topical cantharidin (0.7% weight/volume [w/v]) and is being evaluated for the treatment of molluscum. OBJECTIVES: Our objective was to present pooled safety and efficacy analyses of VP-102 in the treatment of molluscum compared with vehicle. METHODS: Participants aged ≥ 2 years were randomized 3:2 to topical administration of VP-102 or vehicle in two randomized, double-blind, vehicle-controlled phase III trials. Study drug was applied to all baseline and new lesions once every 21 days until clear or for a maximum of four applications. Assessors blinded to treatment counted all lesions at each study visit. All adverse events (AEs) were documented. Data were pooled for analyses. RESULTS: In total, 310 participants received VP-102 and 218 received vehicle. Mean age was 7.5 years (range 2–60) for VP-102 and 6.8 (2–54) for vehicle. Complete clearance of all molluscum lesions at day 84 occurred in 50% of VP-102 participants and 15.6% of vehicle recipients (p < 0.0001). Mean molluscum lesion counts decreased 76% for VP-102 and 0.3% for vehicle at day 84 (p < 0.0001). The most common AEs in the VP-102 group were application site blistering, pruritus, pain, and erythema, which were generally mild or moderate in severity. CONCLUSIONS: Pooled analyses showed a significantly higher percentage of participants with complete molluscum lesion clearance and larger reductions in lesion counts with VP-102 than with vehicle. AEs were anticipated because of the pharmacodynamic properties of cantharidin. TRIAL REGISTRATION: ClinicalTrials.gov identifiers: NCT03377790 (first posted 19 December 2017) and NCT03377803 (first posted 19 December 2017). SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40257-020-00570-8. Springer International Publishing 2021-02-18 2021 /pmc/articles/PMC7973914/ /pubmed/33599960 http://dx.doi.org/10.1007/s40257-020-00570-8 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Original Research Article
Eichenfield, Lawrence F.
Siegfried, Elaine
Kwong, Pearl
McBride, Mark
Rieger, Jayson
Glover, David
Willson, Cynthia
Davidson, Matthew
Burnett, Patrick
Olivadoti, Melissa
Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum
title Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum
title_full Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum
title_fullStr Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum
title_full_unstemmed Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum
title_short Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum Contagiosum
title_sort pooled results of two randomized phase iii trials evaluating vp-102, a drug-device combination product containing cantharidin 0.7% (w/v) for the treatment of molluscum contagiosum
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973914/
https://www.ncbi.nlm.nih.gov/pubmed/33599960
http://dx.doi.org/10.1007/s40257-020-00570-8
work_keys_str_mv AT eichenfieldlawrencef pooledresultsoftworandomizedphaseiiitrialsevaluatingvp102adrugdevicecombinationproductcontainingcantharidin07wvforthetreatmentofmolluscumcontagiosum
AT siegfriedelaine pooledresultsoftworandomizedphaseiiitrialsevaluatingvp102adrugdevicecombinationproductcontainingcantharidin07wvforthetreatmentofmolluscumcontagiosum
AT kwongpearl pooledresultsoftworandomizedphaseiiitrialsevaluatingvp102adrugdevicecombinationproductcontainingcantharidin07wvforthetreatmentofmolluscumcontagiosum
AT mcbridemark pooledresultsoftworandomizedphaseiiitrialsevaluatingvp102adrugdevicecombinationproductcontainingcantharidin07wvforthetreatmentofmolluscumcontagiosum
AT riegerjayson pooledresultsoftworandomizedphaseiiitrialsevaluatingvp102adrugdevicecombinationproductcontainingcantharidin07wvforthetreatmentofmolluscumcontagiosum
AT gloverdavid pooledresultsoftworandomizedphaseiiitrialsevaluatingvp102adrugdevicecombinationproductcontainingcantharidin07wvforthetreatmentofmolluscumcontagiosum
AT willsoncynthia pooledresultsoftworandomizedphaseiiitrialsevaluatingvp102adrugdevicecombinationproductcontainingcantharidin07wvforthetreatmentofmolluscumcontagiosum
AT davidsonmatthew pooledresultsoftworandomizedphaseiiitrialsevaluatingvp102adrugdevicecombinationproductcontainingcantharidin07wvforthetreatmentofmolluscumcontagiosum
AT burnettpatrick pooledresultsoftworandomizedphaseiiitrialsevaluatingvp102adrugdevicecombinationproductcontainingcantharidin07wvforthetreatmentofmolluscumcontagiosum
AT olivadotimelissa pooledresultsoftworandomizedphaseiiitrialsevaluatingvp102adrugdevicecombinationproductcontainingcantharidin07wvforthetreatmentofmolluscumcontagiosum